Methods of Treating Cancer Using Compositions of Antibodies and Carrier Proteins with Antibody Pretreatment

Abstract

Described herein are methods, formulations and kits for treating a patient with cancer with anti-VEGF antibodies and albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes.

1 - 22 . (canceled) 
     
     
         23 . A kit comprising: (a) an amount of albumin-bound chemotherapeutic/anti-VEGF antibody complexes, (b) a unit dose of a sub-therapeutic amount of anti-VEGF antibody, and optionally (c) instructions for use. 
     
     
         24 . A kit comprising: (a) an amount of an albumin-bound chemotherapeutic/anti-VEGF antibody complexes, (b) a unit dose of a sub-therapeutic amount of anti-VEGF antibody, and optionally (c) instructions for use; wherein the unit dose of a sub-therapeutic amount of anti-VEGF antibody is instructed to be administered between about 30 minutes to about 48 hours prior to administering the albumin-bound chemotherapeutic/anti-VEGF antibody complexes; wherein the unit dose of the sub-therapeutic amount of anti-VEGF antibody comprises from about 1% to about 60% of a therapeutic dose of the anti-VEGF antibody; wherein the therapeutic dose of the anti-VEGF antibody is about 5 mg/kg to about 15 mg/kg; wherein the chemotherapeutic is paclitaxel; and wherein the anti-VEGF antibody is bevacizumab or a biosimilar version thereof. 
     
     
         25 . The kit of  claim 24 , wherein the albumin-bound chemotherapeutic/anti-VEGF antibody complexes are lyophilized. 
     
     
         26 . The kit of  claim 24 , wherein the unit dose of the therapeutic amount of anti-VEGF antibody is from 5 to 15 mg/kg. 
     
     
         27 . The kit of  claim 24 , wherein the unit dose of the sub-therapeutic amount of anti-VEGF antibody is from 0.25 mg/kg to 3 mg/kg. 
     
     
         28 . The kit of  claim 24 , wherein the unit dose of the sub-therapeutic amount of anti-VEGF antibody is from 0.5 mg/kg to 2 mg/kg. 
     
     
         29 . The kit of  claim 24 , wherein the unit dose of the sub-therapeutic amount of anti-VEGF antibody comprises from about 5% to about 20% of a therapeutic dose of bevacizumab or a biosimilar version thereof. 
     
     
         30 . The kit of  claim 29 , wherein the unit dose of the sub-therapeutic amount of anti-VEGF antibody comprises about 10% of a therapeutic dose of bevacizumab or a biosimilar version thereof. 
     
     
         31 . A method for treating a patient suffering from a cancer that expresses VEGF, wherein said method comprises administering albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes containing a therapeutically effective amount of the chemotherapeutic to said patient, wherein said patient was administered a sub-therapeutic amount of an anti-VEGF antibody between about 30 minutes and 48 hours prior to said administering of said nanoparticle complexes, wherein said chemotherapeutic is paclitaxel, wherein said anti-VEGF antibody is bevacizumab or a biosimilar version thereof, wherein a therapeutic amount of said anti-VEGF antibody is about 5 mg/kg to about 15 mg/kg, and wherein said sub-therapeutic amount of said anti-VEGF antibody is from about 1 percent to about 60 percent of said therapeutic amount of said anti-VEGF antibody. 
     
     
         32 . A unit-dose formulation of an anti-VEGF antibody, wherein said formulation comprises from about 1% to about 60% of a therapeutic dose of said antibody, wherein said formulation is packaged so as to be administered as a unit dose.